Is fibroblast growth factor 23 a new cardiovascular risk marker in gestational diabetes?

Kizilgul, Muhammed; Kan, Seyfullah; Beysel, Selvihan; Apaydin, Mahmut; Ozcelik, Ozgur; Caliskan, Mustafa; Ozbek, Mustafa; Ozdemir, Seyda; Cakal, Erman.
Arch. endocrinol. metab. (Online) ; 61(6): 562-566, Dec. 2017. tab, graf
Artículo en Inglés | LILACS | ID: biblio-887605

Documentos relacionados

  1. A New Drug Target for Type 2 Diabetes.
  2. Insights from multi-omics integration in complex disease primary tissues.
  3. Influence of autozygosity on common disease risk across the phenotypic spectrum.
  4. Personalized Nutrition by Prediction of Glycemic Responses.
  5. Investigation of the Systemic Immune Inflammation (SII) Index as an Indicator of Morbidity and Mortality in Type 2 Diabetic Retinopathy Patients in a 4-Year Follow-Up Period.
  6. How exposure to chronic stress contributes to the development of type 2 diabetes: A complexity science approach.
  7. Aetiology of Type 2 diabetes in people with a 'normal' body mass index: testing the personal fat threshold hypothesis.
  8. [Relationship between serum 1, 5-anhydroglucitol level and insulin resistance, microvascular complications in type 2 diabetes mellitus].
  9. Increased soluble endoglin levels in newly-diagnosed type 2 diabetic patients are associated with endothelial dysfunction.
  10. Examination of the Complex Molecular Landscape in Obesity and Type 2 Diabetes.